Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-08-31
Based on 127 first isolates · ICU · Skin / wound infection · 2024-09-01 → 2025-08-31
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 52 % (43 %–60 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (93 %–99 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (17 %), Escherichia coli (14 %), Proteus mirabilis (8 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
52 %
8 %
n = 12
meropenem MEM
trend · Pseudomonas aeruginosa reserve
46 %
83 %
n = 12
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
44 %
75 %
n = 12
39 %
75 %
n = 12
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
37 %
0 %
n = 12
ceftriaxone CRO
trend · Escherichia coli
31 %
58 %
n = 12
28 %
33 %
n = 12
28 %
58 %
n = 12
14 %
25 %
n = 12
mecillinam MEC
not for this site
0 %
0 %
n = 12
trimethoprim TMP
not for this site
0 %
0 %
n = 12
nitrofurantoin NIT
not for this site
0 %
0 %
n = 12

Most likely organisms for this profile

Staphylococcus aureus
39 %
Pseudomonas aeruginosa
17 %
Escherichia coli
14 %
Enterococcus faecalis
13 %
Proteus mirabilis
8 %
Citrobacter freundii
7 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.